CDL Nuclear Technologies: Company and Competitor Profile

Company Background

Founded in 1992, CDL Nuclear Technologies is a leading provider of advanced cardiac imaging solutions, specializing in Cardiac PET and PET/CT technologies. The company's mission is to make cutting-edge cardiology imaging equipment accessible to physicians, thereby enhancing diagnostic capabilities and patient care. With nearly three decades of innovation, CDL has become the top provider of custom Cardiac PET and PET/CT suite buildouts in the United States, supporting over 200 labs nationwide.

Key Strategic Focus

CDL Nuclear Technologies focuses on delivering comprehensive, scalable, and integrated cardiac imaging solutions. Their strategic objectives include:

Custom Suite Buildouts: Designing and implementing tailored Cardiac PET and PET/CT suites to meet the specific needs of healthcare facilities.

Mobile Imaging Services: Providing on-demand mobile Rubidium-82 and Flurpiridaz F-18 capabilities, offering flexibility and reducing the need for significant upfront investments.

Comprehensive Support: Offering end-to-end services, including equipment, training, and ongoing support, to ensure seamless integration and operation of imaging technologies.

The company primarily targets independent cardiology practices and hospital cardiology departments, aiming to enhance their diagnostic capabilities and patient outcomes.

Financials and Funding

CDL Nuclear Technologies has demonstrated significant growth and financial stability:

Estimated Revenue: Approximately $47.2 million annually.

Employee Growth: The company has expanded its workforce by 20% in the past year, indicating robust operational growth.

Funding Status: As a privately held company, CDL Nuclear Technologies has not publicly disclosed specific funding rounds or valuations.

Pipeline Development

While specific pipeline candidates and clinical trial stages are not publicly detailed, CDL Nuclear Technologies continues to innovate in cardiac imaging technologies, focusing on:

Advanced Imaging Solutions: Integrating the latest advancements in Cardiac PET and PET/CT to improve diagnostic accuracy.

Flexible Deployment Models: Expanding mobile imaging services to increase accessibility and reduce operational costs for healthcare providers.

Technological Platform and Innovation

CDL Nuclear Technologies distinguishes itself through several key technological innovations:

Proprietary Technologies: Development of custom Cardiac PET and PET/CT suite designs tailored to the unique needs of healthcare facilities.

Scientific Methods: Utilization of advanced imaging techniques, including Cardiac PET, PET/CT, and SPECT, to provide comprehensive myocardial perfusion imaging.

AI-Driven Capabilities: While specific AI applications are not detailed, the company's commitment to innovation suggests ongoing exploration of AI integration to enhance imaging analysis and workflow efficiency.

Leadership Team

The leadership team at CDL Nuclear Technologies comprises experienced professionals dedicated to advancing the company's mission:

Lon Wilson: Chief Executive Officer and Chief Radiation Safety Officer. Lon has been with the company since 2005, serving in various leadership roles including Vice President of Nuclear Cardiology and Molecular PET Operations.

Scott Leya: Chief Financial Officer. Scott joined in 2022, bringing over 30 years of experience in finance, accounting, IT, HR, supply chain, construction management, and operations. Prior to CDL, he was CFO for Primanti Bros. and MedExpress Urgent Care.

Arin Barooah: Chief Growth Officer. Arin plays a pivotal role in driving the company's growth strategies and expanding its market presence.

Chris Baer: Chief Commercial Officer. Chris is responsible for overseeing the company's commercial operations, including sales and marketing strategies.

Strategic Collaborations and Partnerships

CDL Nuclear Technologies has established significant partnerships to enhance its service offerings:

GE HealthCare: In September 2025, CDL entered into an agreement with GE HealthCare to distribute Flyrcado, a cardiac PET radiotracer, through its network. This collaboration aims to broaden the availability of advanced cardiac imaging solutions.

Operational Insights

CDL Nuclear Technologies maintains a strong market position by:

Custom Solutions: Offering tailor-made Cardiac PET and PET/CT imaging suites and mobile imaging options for healthcare providers.

End-to-End Service: Providing integrated support, training, and maintenance to optimize technology deployment and clinical outcomes.

Competitor Profile

CDL Nuclear Technologies operates in a competitive landscape with several key players:

Saad Healthcare: Estimated annual revenue of $58.5 million with 197 employees. The company offers a range of healthcare services, including imaging solutions.

Savannah Court: Generating approximately $20.5 million in annual revenue with 76 employees, focusing on healthcare services centered on patient care.

Sonora Behavioral Health Hospital: Estimated revenue of $44.8 million with 151 employees, providing behavioral health services including diagnostic imaging.

Arizona Arthritis and Rheumatology Research: Around $34 million in annual revenue with 126 employees, specializing in arthritis and rheumatology research and incorporating advanced imaging techniques.